CoChat

Adenovirus-Mediated Gene Therapy in a Mouse Model of Hereditary Tyrosinemia Type I

Overturf, Ken, Al-Dhalimy, Muhsen, Ou, Ching Nan, Finegold, Milton, Tanguay, Robert, Lieber, Andre, Kay, Mark, Grompe, Markus · 1997 · Human Gene Therapy
Cited by 77

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Mice lacking the enzyme fumarylacetoacetate hydrolase (FAH) have symptoms similar to humans with the disease hereditary tyrosinemia type I (HT1). FAH-deficient mice were injected with a first-generation adenoviral vector expressing the human FAH gene and followed for up to 9 months. Nontreated FAH mutant control mice died within 6 weeks from fulminant liver failure, whereas FAH adenovirus-infected animals survived until sacrifice at 2–9 months. Nine of 13 virus-treated animals developed hepatocellular cancer. Immunohistochemical analysis revealed a mosaic of FAH-deficient and FAH-positive cells in all animals and liver function tests were improved compared to controls. Even mice harvested 9 months after viral infection had >50% FAH-positive cells. These results demonstrate the strong selective advantage of FAH-expressing cells in an FAH-deficient liver but also illustrate the danger of carcinomas arising from FAH-deficient hepatocytes in HT1. In this study, we tested the effectiveness of a fumarylacetoacetate hydrolase (FAH)-expressing adenovirus in the treatment of a mouse model of the human disease hereditary tyrosinemia type I (HT1). Thirteen mice were treated with the recombinant adenovirus and analyzed at intervals ranging from 2 to 9 months after injection. All treated mice had improved survival, weight gain, and liver function tests. A high percentage (>20%) of hepatic cells remained FAH-positive, even 6–9 months post injection. However, 9 of 13 mice developed either microscopic or macroscopic hepatocellular carcinomas originating from nontransduced FAH-negative cells. This report demonstrates that adenoviral gene therapy of HT1 is aided by the strong selective advantage of FAH-expressing cells, but also that adenoviral gene therapy does not obviate the tumor risk inherent in HT1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/hum.1997.8.5-513

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 77

Metadata

Authors
Overturf, K., Al-Dhalimy, M., Ou, C. N., Finegold, M., Tanguay, R., Lieber, A., Kay, M., & Grompe, M.
Venue
Human Gene Therapy
Published
1997-03-20
Volume
8
Issue
5
Pages
513-521
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2031631992
Cited by
77
References
6
FWCI
3.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.